KR960704576A - CD40에 대한 항체(Antibodies to CD40) - Google Patents

CD40에 대한 항체(Antibodies to CD40)

Info

Publication number
KR960704576A
KR960704576A KR1019960701469A KR19960701469A KR960704576A KR 960704576 A KR960704576 A KR 960704576A KR 1019960701469 A KR1019960701469 A KR 1019960701469A KR 19960701469 A KR19960701469 A KR 19960701469A KR 960704576 A KR960704576 A KR 960704576A
Authority
KR
South Korea
Prior art keywords
binding
ligand
monoclonal antibodies
monoclonal antibody
therapeutic composition
Prior art date
Application number
KR1019960701469A
Other languages
English (en)
Inventor
윌리엄 씨. 3세 팬슬로우
조디 자포네
마크 앨더슨
리차드 제이. 아미티지
Original Assignee
크리스토퍼 엘. 와이트
임뮤넥스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스토퍼 엘. 와이트, 임뮤넥스 코포레이션 filed Critical 크리스토퍼 엘. 와이트
Publication of KR960704576A publication Critical patent/KR960704576A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 CD40에 특이적으로 결합하며 CD40의 CD40 리간드에의 결합을 차단 할 수 있는 모노클로날 항체 및 결합 단백질을 제공한다.

Description

CD40에 대한 항체(Antibodies to CD40)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 가용성 CD40의 CD40 리간드-발현 세포에의 결합을 적어도 약 90% 억제하는 것으로 관찰된 것에 의해 결정된 바와 같은, 사람 CD40 분자에 특이적으로 결합하여 CD40 분자가 CD40 리간드에 결합하는 것을 억제하는 모노클로날 항체.
  2. 제1항에 있어서, 쥐 및 사람 모노클로날 항체로 구성된 군으로부터 선택된 모노클로날 항체.
  3. 제2항에 있어서, HuCD40-M2(ATCC HB 11459) 및 가용성 CD40의 CD40 리간드-발현 세포에의 결합을 적어도 약 90% 억제하는 것으로 관찰된 것에 의해 결정된 바와 같은, HuCD40M2의 CD40 리간드 억제 특성을 갖는 모노클로날 항체로 구성된 군으로부터 선택된 쥐 모노클로날 항체.
  4. 제3항에 있어서, 쥐 하이브리도마 HuCD40-M2(ATCC HB 11459)에 의해서 생산된 쥐 모노클로날 항체.
  5. 제1 내지 4항 중 어느 한 항에 따른 항체를 코딩하는 DNA 서열에 의해 코딩된 CD40-결합 도메인을 포함하는, CD40에 특이적으로 결합하는 결합 단백질, 또는 CD40에 특이적으로 결합하는 그의 부분.
  6. 제5항에 있어서, 인간화 모노클로날 항체, 단쇄 Fv 단편 및 2가 Fv 단편으로 구성된 군으로부터 선택된 결합 단백질.
  7. 제1 내지 4항 중 어느 한 항에 따른 CD40 모노클로날 항체 및 생리적으로 허용되는 담체 또는 희석제를함유하는 치료제 조성물.
  8. 제5항 또는 6항의 CD40 모노클로날 항체 및 생리적으로 허용되는 담체 또는 희석제를 함유하는 치료제 조성물.
  9. 제7항 또는 8항 중 어느 한 항에 따른 치료제 조성물 효과량을 투여하는 것으로 이루어진, CD40 리간드-매개 면역 또는 염증 반응을 억제하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960701469A 1993-10-01 1994-09-02 CD40에 대한 항체(Antibodies to CD40) KR960704576A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13054193A 1993-10-01 1993-10-01
US08/130,541 1993-10-01
PCT/US1994/009984 WO1995009653A1 (en) 1993-10-01 1994-09-02 Antibodies to cd40

Publications (1)

Publication Number Publication Date
KR960704576A true KR960704576A (ko) 1996-10-09

Family

ID=22445171

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960701469A KR960704576A (ko) 1993-10-01 1994-09-02 CD40에 대한 항체(Antibodies to CD40)

Country Status (15)

Country Link
US (1) US5801227A (ko)
EP (1) EP0724456B1 (ko)
JP (1) JP3675819B2 (ko)
KR (1) KR960704576A (ko)
AT (1) ATE255906T1 (ko)
AU (1) AU686230B2 (ko)
CA (1) CA2172376C (ko)
DE (1) DE69433406T2 (ko)
DK (1) DK0724456T3 (ko)
ES (1) ES2211884T3 (ko)
FI (1) FI961285A0 (ko)
NO (1) NO961151D0 (ko)
NZ (1) NZ273504A (ko)
PT (1) PT724456E (ko)
WO (1) WO1995009653A1 (ko)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
PT812206E (pt) * 1995-03-01 2002-11-29 Immunex Corp Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
AU740227B2 (en) * 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
ES2249907T3 (es) * 1998-05-23 2006-04-01 Leiden University Medical Center Anticuerpos de union cd40 y peptidos ctl para el tratamiento de tumores.
EP2039368A3 (en) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU1072701A (en) * 1999-10-04 2001-05-10 Chiron Corporation Cd40 antagonist for treating psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU3662101A (en) 2000-02-01 2001-08-14 Tanox Inc Cd40-binding apc-activating molecules
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
EP1717251B1 (en) 2000-10-02 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Therapy for B-cell malignancies using human anti-CD40 antibodies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
JP4463475B2 (ja) 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2544852A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
CN101351478A (zh) * 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
EP1945260B1 (en) * 2005-11-01 2012-10-24 Novartis AG Uses of anti-cd40 antibodies
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
EP2589654A1 (en) * 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
DK2914627T3 (da) 2012-10-30 2021-07-12 Apexigen Inc Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3303395T3 (da) 2015-05-29 2020-01-27 Abbvie Inc Anti-cd40-antistoffer og anvendelser deraf
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
ES2906823T3 (es) 2015-09-30 2022-04-20 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a CD40 humano y métodos de uso
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
EA201892362A1 (ru) 2016-04-18 2019-04-30 Селлдекс Терапьютикс, Инк. Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
WO2018088850A2 (ko) * 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
CN117500816A (zh) 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules

Also Published As

Publication number Publication date
AU686230B2 (en) 1998-02-05
CA2172376C (en) 2008-11-18
NO961151L (no) 1996-03-21
PT724456E (pt) 2004-04-30
EP0724456B1 (en) 2003-12-10
JPH09504169A (ja) 1997-04-28
NO961151D0 (no) 1996-03-21
JP3675819B2 (ja) 2005-07-27
FI961285A (fi) 1996-03-20
DE69433406D1 (de) 2004-01-22
NZ273504A (en) 1997-12-19
FI961285A0 (fi) 1996-03-20
EP0724456A4 (en) 1997-07-02
US5801227A (en) 1998-09-01
CA2172376A1 (en) 1995-04-13
EP0724456A1 (en) 1996-08-07
ES2211884T3 (es) 2004-07-16
AU7681994A (en) 1995-05-01
DK0724456T3 (da) 2004-04-13
DE69433406T2 (de) 2004-10-07
WO1995009653A1 (en) 1995-04-13
ATE255906T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
KR960704938A (ko) Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
ATE208820T1 (de) Humanisierte antikoerper
DK1265929T3 (da) Anti-C2/C2a-inhibitorer til komplement aktivering
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
DE69939813D1 (de) Inhibitoren der komplement-aktivierung
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
Kostelny et al. Humanization and characterization of the anti‐HLA‐DR antibody 1D10
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
DK0720624T3 (da) Omdirigering af antistoffer
HRP20120975T1 (hr) Terapeutska upotreba anti-cs1 antitijela
MOCIKAT et al. Antigen Binding and Effector Functions of a Chimeric Antibody with a Deletion of the CH 1 Domain and Non-Covalently Associated ϰ Chains
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
Şahín et al. New monoclonal antibody specific for a 6.5 kDa glycoprotein which presents mainly on a B cell of chronic lymphocytic leukemia (CLL)
KR950016780A (ko) 신규 모노클로날 항체

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid